Focus on HIV Care

Back to articles

Resistance to HIV medications rare during preexposure prophylaxis

KEY POINT

Primary drug resistance to either tenofovir disoproxil fumarate (TDF) and/or emtricitabine (FTC, Truvada—Gilead) was rare in people who acquired HIV infection while enrolled in a preexposure prophylaxis (PrEP) trial, according to an analysis of data published in AIDS.

SOURCES

Delaugerre C, et al. Drug resistance among patients who acquired HIV infection in a PrEP trial. AIDS. 2018;[Epub ahead of print].